Terren O'Connor

Associate
Full contact info

I enjoy building long-term relationships with clients, guiding them through all stages of development, from startup to IPO and beyond.

Passions

Alpine skiing

Trying new recipes

Electric mountain biking

Experience

Red Tree Venture Capital – $108 Million Oversubscribed Series B Financing

March 6, 2023

Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.

Related contacts

Terren O'Connor
Associate, San Diego
Arman Sagart
Associate, San Diego
Michelle Hunt
Associate
Tom Coll
Partner, San Diego

Flexion Therapeutics Agrees to Sell to Pacira BioSciences

October 13, 2021

Cooley advised Flexion Therapeutics, a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, on its agreement to sell to Pacira BioSciences. Lawyers Miguel Vega, Kevin Cooper, Sean Clayton and Matthew Silverman led the Cooley team advising Flexion.

Related contacts

Miguel J. Vega
Partner, Boston
Kevin Cooper
Partner, New York
Matthew D. Silverman
Special Counsel, San Diego
Ivor Elrifi
Partner, New York
Stephanie Gentile
Partner, New York
Patrick Flanagan
Partner, New York
Jason Savich
Partner, San Francisco
Jacqueline Grise
Partner, Washington DC
Phil Mitchell
Partner, New York
Eileen Marshall
Partner, Washington DC
Peter Adams
Partner, San Diego
Mischi a Marca
Partner, San Francisco
David Navetta
Partner, Colorado
Natasha Leskovsek
Of Counsel, Washington DC
Geoffrey Spolyar
Partner, Boston
Edmond Lay
Associate, San Diego
Luke X. Blackett
Associate, San Francisco
Terren O'Connor
Associate, San Diego
Patrick Sharma
Associate, Los Angeles Santa Monica
Ross Eberly
Partner, Los Angeles Santa Monica
Rubin Waranch
Associate, Washington DC
Josh Rosenholtz
Associate, Colorado
Allison Kutner
Associate, New York
Andrew Epstein
Associate, Seattle
Jennifer Shanley
Special Counsel, New York
Dani Nazemian
Special Counsel, San Diego
Alexandra Leavy
Associate, New York
Kristopher Kleiner
Special Counsel, Colorado

Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion

August 5, 2021

Cooley advised Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics, on its agreement to sell to Bayer AG for a purchase price of $1.5 billion and up to $500 million in success-based milestone payments. Partners Barbara Borden and Karen Deschaine led the Cooley team advising Vividion.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Karen Deschaine
Partner, San Diego
Kay Chandler
Partner, San Diego
Rowook Park
Partner, San Diego
Terren O'Connor
Associate, San Diego
Alessandra Murata
Partner, Palo Alto
Austin Holt
Associate, Los Angeles Santa Monica
Todd Gluth
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Megan Browdie
Partner, Washington DC
Ross Eberly
Partner, Los Angeles Santa Monica
Daniel Lac
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Phil Mitchell
Partner, New York
David Navetta
Partner, Colorado

Turning Point Therapeutics - $192 Million IPO

April 17, 2019

Cooley advised Turning Point Therapeutics on its $191.5 million initial public offering of 10,637,500 shares of common stock. Turning Point Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol “TPTX,” is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Partners Charles Bair and Karen Anderson led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Karen Deschaine
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Terren O'Connor
Associate, San Diego
Alexa M. Smith (Ekman)
Associate, San Diego

TRACON Pharmaceuticals Completes Initial Public Offering

February 13, 2015

Cooley advised TRACON Pharmaceuticals on its initial public offering, as well as a concurrent private placement. TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company now trades on the Nasdaq Global Market under the symbol "TCON."

Related contacts

Charlie Kim
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Kristin VanderPas
Partner, San Francisco
Dani Nazemian
Special Counsel, San Diego
Terren O'Connor
Associate, San Diego
Phil Mitchell
Partner, New York
View more